JAK inhibitors exert large potential as a comprehensive intervention for T1D, as they are uniquely positioned to address immune as well as endocrine dysfunctional JAK-STAT molecular pathways involved in disease pathophysiology. The gene discussed is SOAT1; the disease is type 1 diabetes mellitus.